Glaukos reports preliminary Q4 2025 net sales ~$143M (+36% YoY); reaffirms FY2026 guidance $600-620M

GLAUKOS Corp

2025-FY EPS reported -$3.28 revenue$507,442,000

Q4 2025 net sales ~$143M (+36% YoY); FY2025 net sales ~$507M (+32% YoY).
U.S. Glaucoma net sales FY2025 $299M, including iDose TR $136M; Corneal Health $86M.
Cash & equivalents $283M, no debt at Q4 end; 2026 revenue guidance reaffirmed $600-620M.
International Glaucoma net sales FY2025 $122M; Q4 alone ~$33M.
Company will report full Q4 & FY2025 results on Feb 17, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.